WILMINGTON — Prelude Therapeutics has named Bryant Lim as its next chief financial officer, a role he has been serving in on an interim basis since April 2024. His position became official on Feb. 4.
Lim had stepped in the role after Prelude’s previous top financial executive, Laurent Chardonnet, stepped down from the post while consulting for the biotech company until October. Lim will also continue to serve as Prelude’s chief legal officer and corporate secretary, according to company representatives.
“Bryant’s broad experience in leadership roles at emerging biotech companies is especially valuable as Prelude continues to evolve and grow,” Prelude Therapeutics Founder and CEO Kris Vaddi said in a prepared statement.
Prelude Therapeutics is an upstart Wilmington company that has drawn international attention for its work on small molecule inhibitors, a developing therapy that is more targeted in approach with fewer side effects than traditional cancer therapies like chemotherapy or radiation. The company moved into its new headquarters at the Chestnut Run Innovation and Science Park in early 2024. In the last year, Prelude also released promising data on its closely-watched drug candidate PRT3789.
Vaddi and Lim both worked at Incyte Corporation, another biopharmaceutical company working to treat rare forms of diseases and cancers. Vaddi worked there for 14 years where he was on the team that created Jakafi, a JAK inhibitor that treats certain types of blood cancer. Meanwhile, Lim worked as the vice president of legal at Incyte for four years and had most recently served as its Global Chief Compliance Officer until 2018.
Prior to Incyte, Lim held roles of increasing responsibility in legal affairs and business development at ViroPharma Incorporated, Merck, and Morgan, Lewis & Bockius LLP. He began his career working for a law clerk for a federal judge.
Lim also served as senior vice president, general counsel and chief business officer at Idera Pharmaceuticals, a biotech company that researched rare diseases that was later rebranded to Aceragen. He worked there between October 2018 to February 2023, months before the company went bankrupt.
As Prelude Therapeutics chief financial officer, Lim will earn a base salary of $483,000 and be eligible for a potential bonus up to 40% of his salary, according to documents filed with the U.S. Securities and Exchange Commission. That bonus is available once the company achieves key milestones set by the company’s board of directors.
Prelude Therapeutics board of directors has already approved an option for Lim to purchase 200,000 shares of the Company’s common stock, which will vest on the first anniversary of the grant date.
